• 30897 Citations
  • 73 h-Index
1982 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 42 Similar Profiles
Stomach Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Survival Medicine & Life Sciences
Stomach Medicine & Life Sciences
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1982 2019

Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer

Kim, H. S., Hwang, I. G., Min, H. Y., Bang, Y. J. & Kim, W. H., 1 May 2019, In : Oncology Letters. 17, 5, p. 4383-4392 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
BRCA2 Protein
Stomach Neoplasms
Immunohistochemistry
Messenger RNA
Reverse Transcription

KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer

Bang, Y. J., Van Cutsem, E., Fuchs, C. S., Ohtsu, A., Tabernero, J., Ilson, D. H., Hyung, W. J., Strong, V. E., Goetze, T. O., Yoshikawa, T., Tang, L. H., Hwang, P. M. T., Webb, N., Adelberg, D. & Shitara, K., 1 Mar 2019, In : Future Oncology. 15, 9, p. 943-952 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Stomach Neoplasms
Esophagogastric Junction
Drug Therapy
Stomach
Adenocarcinoma

A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer

Bang, Y. J., Kang, Y. K., Ng, M., Chung, H. C., Wainberg, Z. A., Gendreau, S., Chan, W. Y., Xu, N., Maslyar, D., Meng, R., Chau, I. & Ajani, J. A., 1 Feb 2019, In : European Journal of Cancer. 108, p. 17-24 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Esophagogastric Junction
Stomach
Disease-Free Survival
Placebos
Neoplasms

Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design

Moehler, M., Ryu, M. H., Dvorkin, M., Lee, K-W., Coşkun, H., Wong, R., Chung, H. C., Poltoratsky, A., Tsuji, A., Yen, C. J., Muntean, A. S., Le Sourd, S., Vaccaro, G. M., Overton, L., Boku, N., Wainberg, Z. A., Patel, M., Sharma, M., Xiong, H., Conti, I. & 2 othersTaieb, J. & Bang, Y. J., 1 Feb 2019, In : Future Oncology. 15, 6, p. 567-577 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Stomach Neoplasms
Esophagogastric Junction
Stomach
oxaliplatin
Maintenance

SOURCE: A registry-based prediction model for overall survival in patients with metastatic oesophageal or gastric cancer

van den Boorn, H. G., Abu-Hanna, A., Ter Veer, E., van Kleef, J. J., Lordick, F., Stahl, M., Ajani, J. A., Guimbaud, R., Park, S. H., Dutton, S. J., Bang, Y. J., Boku, N., Mohammad, N. H., Sprangers, M. A. G., Verhoeven, R. H. A., Zwinderman, A. H., van Oijen, M. G. H. & van Laarhoven, H. W. M., 1 Feb 2019, In : Cancers. 11, 2, 187.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
Esophageal Neoplasms
Stomach Neoplasms
Registries
Survival
Calibration